Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo-controlled, Randomized Phase III Trial to Assess the Safety and Efficacy of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age.

NCT03211247 is registered in ClinicalTrials.gov with DBV Technologies as lead sponsor.

NCT NCT03211247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03211247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo-controlled, Randomized Phase III Trial to Assess the Safety and Efficacy of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age.
Lead sponsor
DBV Technologies
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2017
Completion date
April 27, 2022
Enrollment
414 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

peanut allergy